Research review and update: IQUIX (levofloxacin 1.5%).
McDonald
Marguerite B
MB
Department of Opthalmology, Tulane University School of Medicine, New Orleans, LA 70115, USA.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001419:Bacteria / Q000235:genetics; D004269:DNA, Bacterial / Q000187:drug effects; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D013666:Tears / Q000378:metabolism; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D009883:Ophthalmic Solutions; D064704:Levofloxacin; D015242:Ofloxacin